Gilead

News
Gilead Sciences

Gilead needs deal-maker CEO after Milligan quits

Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of its CAR-T therapy, after CEO John Milligan announced he is to step down at the

News
HIV budding Color

ViiV prepares another two-drug HIV filing

ViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination cutting the number of drugs taken to suppress the disease from three to two, f